Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Intra-Cellular Therapies $500 million stock offering
The shares are listed on the Nasdaq Global Select Market
Nurix Therapeutics $175 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Market
Biodesix $55 million follow-on offering
The common stock is listed on the Nasdaq Global Market
Adagene $100 million at-the-market offering
We advised Adagene on the offering
Stoke Therapeutics $125 million stock and pre-funded warrants offering
The common stock is listed on the Nasdaq Global Select Market
AnHeart Therapeutics acquisition by Nuvation Bio
We are advising AnHeart Therapeutics on the acquisition
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Haleon $3.1 billion secondary offering
The shares are listed on the NYSE
Smith+Nephew $1 billion notes offering
We advised the issuer on the SEC-registered offering